For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230306:nRSF9975Ra&default-theme=true
RNS Number : 9975R Morgan Stanley Capital Services LLC 06 March 2023
Ap34
FORM 38.5(a) (EPT/RI)
IRISH TAKEOVER PANEL
DEALING DISCLOSURE UNDER RULE 38.5(a) OF THE IRISH
TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022
BY A CONNECTED EXEMPT PRINCIPAL TRADER WITH
RECOGNISED INTERMEDIARY STATUS AND DEALING IN
A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
(a) Name of exempt principal trader: Morgan Stanley Capital Services LLC
(b) Name of offeror/offeree in relation to whose relevant securities this Horizon Therapeutics plc
form relates:
Use a separate form for each offeror/offeree
(c) Name of the party to the offer with which exempt principal trader is Horizon Therapeutics plc
connected: (Note 1)
(d) Date dealing undertaken: 03 March 2023
(e) In addition to the company in 1(b) above, is the exempt principal N/A
trader also making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER (Note 2)
Where there have been dealings in more than one class of relevant securities
of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as
appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
Ap35
(a) Purchases and sales
Class of Purchases/ Total Highest Lowest
relevant
sales
number of
price per
price per
security
securities
unit paid/
unit paid/
(Note 3)
received
received
0.0001 ordinary shares Purchase 1,493 110.3706 USD 109.9450 USD
0.0001 ordinary shares Sale 7,345 110.4000 USD 110.0500 USD
(b) Cash-settled derivative transactions
Class of Product Nature of dealing Number of Price per
relevant
description
e.g. opening/closing
reference
unit (Note 5)
security e.g. CFD
a long/short position,
securities
increasing/reducing a (Note 4)
long/short position
0.0001 ordinary shares CFD increasing a short position 2 110.0500 USD
0.0001 ordinary shares CFD increasing a short position 900 110.2386 USD
0.0001 ordinary shares CFD increasing a short position 100 110.2386 USD
0.0001 ordinary shares CFD increasing a long position 16 110.4000 USD
0.0001 ordinary shares CFD reducing a short position 6,984 110.4000 USD
(c) Stock-settled derivative transactions (including
options)
(i) Writing, selling, purchasing or varying
Class of Product Writing, Number Exercise Type Expiry Option
relevant
description
purchasing,
of
price per e.g.
date
money
security
e.g. call option
selling,
securities
unit
American,
paid/
varying etc.
to which
European
received
option
etc.
per unit
relates
(Note 4)
N/A N/A N/A N/A N/A N/A N/A N/A
(ii) Exercise
Class of Product Exercising/ Number of Exercise price
relevant
description
exercised
securities
per unit
security
e.g. call option
against (Note 5)
N/A N/A N/A N/A N/A
(d) Other dealings (including transactions in respect of
new securities)
Class of relevant security Nature of Details Price per unit
dealing
(if applicable)
e.g. subscription,
(Note 5)
conversion,
exercise
N/A N/A N/A N/A
Ap36
3. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or
understanding, formal or informal, relating to relevant securities which may
be an inducement to deal or refrain from dealing entered into by the exempt
principal trader making the disclosure and any party to the offer or any
person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there
are no such agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to
options or derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting
rights or future acquisition or disposal of any relevant securities to which
any derivative referred to on this form is referenced. If none, this should be
stated.
None
Date of disclosure: 06 March 2023
Contact name: Craig Horsley
Telephone number: +44 141 245-7736
Public disclosures under Rule 38 of the Rules must be made to a Reg`ulatory
Information Service.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ISEKQLBBXXLFBBQ